clinical associate professor at the University of Wisconsin-Madison, School of Nursing, Women's Health NP Program.
Diethylstilbestrol (DES) Update: Recommendations for the Identification and Management of DES-Exposed Individuals
Article first published online: 24 DEC 2010
2003 American College of Nurse Midwives
Journal of Midwifery & Womens Health
Volume 48, Issue 1, pages 19–29, January-February 2003
How to Cite
Hammes, B. and Laitman, C. J. (2003), Diethylstilbestrol (DES) Update: Recommendations for the Identification and Management of DES-Exposed Individuals. Journal of Midwifery & Womens Health, 48: 19–29. doi: 10.1016/S1526-9523(02)00370-7
This work was supported by the University of Wisconsin Center for Women's Health and Women's Health Research (A National Center of Excellence in Women's Health), Madison, WI; the U.S. Public Health Service's Centers for Disease Control and Prevention, Atlanta, GA; and PHS Office on Women's Health, Washington, DC (Contract No. 00T00225101D).
- Issue published online: 24 DEC 2010
- Article first published online: 24 DEC 2010
- breast cancer;
- clear cell adenocarcinoma
Diethylstilbestrol (DES) was etiologically linked to clear cell adenocarcinoma of the vagina in 1971. This article reviews on-going research and emerging information relevant to DES-related health risks, thereby enabling women's health care providers to maintain an evidence-based practice for their DES-exposed patients. To accomplish these goals, the Center for Disease Control and Prevention (CDC) has initiated a national education campaign. This article describes the reasons for this new initiative, the target audiences, the DES historical framework (including major studies and findings), and populations that are affected. Clinical steps for the identification and management of the DES-exposed individual and resultant implications for midwifery and women's health practices are reviewed.